February 25, 2020 / 7:07 AM / a month ago

BRIEF-Herantis Announces Topline Results Of Phase 1-2 CDNF Trial

Feb 25 (Reuters) - Herantis Pharma Oyj:

* HERANTIS PHARMA PLC ANNOUNCES TOPLINE RESULTS OF PHASE 1-2 CDNF TRIAL

* HERANTIS PHARMA OYJ - TOPLINE ANALYSIS CONFIRMS POSITIVE SAFETY AND TOLERABILITY OF CDNF IN ADVANCED-STAGE PARKINSON’S DISEASE PATIENTS, WITH ENCOURAGING BIOLOGICAL RESPONSES AS MEASURED BY PET IMAGING IN SOME PATIENTS

* HERANTIS PHARMA OYJ - RESULTS FROM SECOND PART OF TRIAL, IN WHICH ALL PATIENTS WILL RECEIVE CDNF FOR AN ADDITIONAL SIX MONTHS, ARE EXPECTED IN Q3 2020 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below